Introduction
With sales for the top 50 pharma companies forecast to decline by 1.6% during 2010–16, many leading drugmakers are looking to expand into markets which offer long-term growth, limited competition, and are relatively low risk. One such area is biosimilars, which has attracted both innovative biologics players and generics players alike.
Features and benefits
- Insight into why pharma are tapping into the biosimilars market
- Analysis of biosimilar deal trends among the top 50 pharma companies
- Insight into the top 50 pharma companies active in biosimilars
- Review of the top 50 pharma companies that plan to enter the biosimilars market in the near future
- Summary of the top 50 pharma companies plan to avoid biosimilars
Highlights
Of the companies analyzed, each of the eight generics companies ranked among the top 50 pharma companies have an active interest in biosimilars, reflecting the fact that such products have the opportunity increase the profit margin of generics companies.
Many innovative pharma companies have also entered the biosimilars arena with further companies such as Boehringer Ingelheim showing signs of interest.
However, a number of companies such as AstraZeneca, Bayer, and Roche have stated that they have no plans to enter the biosimilars market, instead maintaining their innovative focus.
Your key questions answered
- Understand how and why different corporate pharma companies are targeting biosimilars
- Examine why some companies have opted not to enter this sector
현재위치 : 
